TECENTRIQ®
atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE



Not an actual patient/caregiver; image is AI generated

Your Guide to TECENTRIQ

for stage 3 dMMR colon cancer after surgery

dMMR=mismatch repair deficient.

WHAT IS TECENTRIQ?

TECENTRIQ is a prescription medicine used to treat:

Adults and children 2 years of age and older with a type of colon cancer. TECENTRIQ may be used with a fluoropyrimidine and oxaliplatin medicine:

- to help prevent your colon cancer from coming back after your tumor(s) have been removed by surgery, **and**
- you have stage 3 colon cancer, and your tumor has been shown by a laboratory test to be mismatch repair deficient (dMMR).

It is not known if TECENTRIQ is safe and effective when used in children:

- younger than 2 years of age for the treatment of colon cancer.

SELECT IMPORTANT SAFETY INFORMATION

TECENTRIQ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Please see pages 19-22 and full Prescribing Information for additional Important Safety Information.

Getting started

Living with colon cancer can be overwhelming. You've made it through one major hurdle with surgery, and you may be wondering what comes next. This guide is here to help you understand more about colon cancer, next steps, and treatment with TECENTRIQ.



Not an actual patient/caregiver; image is AI generated

Table of contents

pages

4-7	Understanding colon cancer
8	How TECENTRIQ works
10-11	How TECENTRIQ can help
12-13	How to receive TECENTRIQ
14-15	Side effects and tips on how to manage them
16-17	Help paying for TECENTRIQ
18	Information and support for colon cancer
19-22	Important Safety Information
23	Glossary of medical terms

Please see full Prescribing Information and additional Important Safety Information throughout this brochure.

TECENTRIQ® atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

Understanding colon cancer

If you have been diagnosed with colon cancer, you are not alone. It's the:

FOURTH MOST COMMON CANCER AMONG BOTH MEN AND WOMEN

How colon cancer starts

The colon is part of the large intestine, which is part of the digestive system. The digestive system breaks down the food you eat so your body can use it.

Colon cancer starts when cells in your colon begin to grow abnormally. Often, cancer begins with small growths called polyps that form inside your colon. Over time, some polyps can turn into cancer.

Symptoms of colon cancer

Colon cancer symptoms can be different for each person. But common symptoms may include:


- Changes in bathroom habits, such as frequent diarrhea or constipation
- Rectal bleeding or blood in the stool
- Belly area discomfort such as cramps, gas, or pain
- Feeling like you haven't completely emptied your bowels when you go to the bathroom
- Weakness or tiredness
- Weight loss without trying

Experiencing these symptoms does not necessarily mean you have colon cancer. But if you have any of these symptoms, talk to your doctor. They will have the knowledge and tools needed for a proper diagnosis.


Please see full Prescribing Information and additional Important Safety Information throughout this brochure.

Stages of colon cancer


Doctors use cancer stages to describe how far cancer has spread in your body. They include:




Stage 0: Cancer cells are only found in the innermost layer of the colon




Stage 1: Cancer cells spread past the inner layer into the next layers of the colon wall



Stage 2: Cancer has spread to or past the outermost layer of the colon



Stage 3: Cancer has spread from the colon wall to nearby lymph nodes



Stage 4: Cancer has spread to other parts of the body, such as the liver or lungs

If you have stage 3 dMMR colon cancer after surgery, your doctor can prescribe TECENTRIQ + chemotherapy* to help keep your cancer from coming back.

*Chemotherapy=a fluoropyrimidine and oxaliplatin.

TECENTRIQ® atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

What is a biomarker?

When you were diagnosed, your doctor tested you for different types of biomarkers.



A biomarker is a biological molecule that doctors can find in your blood, body fluids, or tissues. It shows whether something normal or abnormal is happening in your body—or that you have a certain condition or disease.



A common biomarker in colon cancer is dMMR. Having the dMMR biomarker means that the part of your cells that usually fixes mistakes in DNA isn't working the way it should.

When your doctor knows your tumor has this biomarker, they can better predict how likely a specific treatment will work for you. That will help them create the best treatment plan for you.



Your biomarker results help your doctor create a personalized treatment plan.

SELECT IMPORTANT SAFETY INFORMATION

Possible serious side effects with TECENTRIQ include, but are not limited to, lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, skin problems, problems in other organs, severe infusion reactions, and complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).

Please see full Prescribing Information and additional Important Safety Information throughout this brochure.

Colon cancer treatments

Your treatment plan may include surgery, chemotherapy, immunotherapy, radiation, or a combination of these.

Your doctor may recommend additional treatment after surgery. This doesn't mean your surgery failed. But, your doctor may suggest treatment after surgery, called adjuvant treatment. This extra treatment can help lower the chances of cancer coming back.



Colon cancer can return in 1 in 3 patients after surgery.

One type of immunotherapy is TECENTRIQ. Immunotherapy is a treatment that uses your immune system to fight cancer. TECENTRIQ may be an option if you:

- have stage 3 colon cancer
- tested positive for the dMMR biomarker
- had surgery

There are 2 parts of treatment with TECENTRIQ:

Part 1	Part 2
TECENTRIQ + chemotherapy for 6 months	TECENTRIQ alone for 6 months

Your doctor will know if TECENTRIQ is right for you.

TECENTRIQ® atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

TECENTRIQ is a cancer immunotherapy


Immunotherapy, such as TECENTRIQ, works differently than traditional chemotherapy.

In order to understand how immunotherapy works, you need to understand the immune system. The immune system helps protect your body against infection, illness, and disease. When you have colon cancer, cancer cells can hide from your immune system. That means the immune system can't attack cancer cells like it normally would.


Traditional chemotherapy works throughout the body to destroy fast-growing cells, including both cancer cells and certain healthy cells.

Immunotherapy uses a person's own immune system to fight cancer. It boosts the immune system to make it easier for your immune cells to find and attack cancer cells. Immunotherapies, like TECENTRIQ, may also affect healthy cells.

Chemotherapy attacks cancer cells and healthy cells



Immunotherapy uses immune cells to attack cancer cells



In some cases, chemotherapy and immunotherapy are given together. That's because sometimes, they are better at treating certain types of cancer together than when each treatment is given alone.

Please see full Prescribing Information and additional Important Safety Information throughout this brochure.


Not an actual patient; image is AI generated

SELECT IMPORTANT SAFETY INFORMATION (CONT'D)

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems

- cough
- shortness of breath
- chest pain

TECENTRIQ® atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

TECENTRIQ + chemotherapy may keep your colon cancer from coming back

How TECENTRIQ was studied

Researchers tested TECENTRIQ + chemotherapy in a large clinical trial with 712 people who:

- had stage 3 colon cancer
- tested positive for the dMMR biomarker*
- had surgery

The study compared 2 treatment approaches:

Group 1:

TECENTRIQ + chemotherapy for 6 months

TECENTRIQ alone for 6 months

Group 2:

Chemotherapy alone for 6 months

Chemotherapy=mFOLFOX6 (oxaliplatin + leucovorin + fluorouracil).

*dMMR is a biomarker that can be found in your tumor through a biomarker test. Cancers positive for dMMR stand out to your immune system, making them susceptible to immunotherapy. Your biomarker results help your doctor create a personalized treatment plan.

Please see full Prescribing Information and additional Important Safety Information throughout this brochure.

TECENTRIQ lowered the risk of colon cancer returning after surgery

Researchers looked at 2 outcomes of the study:

- The overall risk of the cancer returning over time
- How many people remained cancer-free at 3 years



Overall, **people who took TECENTRIQ + chemotherapy were 50% less likely to have their cancer return** compared with chemotherapy alone

At 3 years:

86% of patients who took TECENTRIQ + chemotherapy remained cancer-free	**76%** of patients who took chemotherapy alone and did not receive TECENTRIQ remained cancer-free

SELECT IMPORTANT SAFETY INFORMATION (CONT'D)

Intestinal problems

- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdomen) pain or tenderness

TECENTRIQ® atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

There are 2 ways to receive treatment: infusions or injections

Treatment with TECENTRIQ happens in 2 parts. In the first part, TECENTRIQ is paired with chemotherapy for the first 6 months. Because chemotherapy is given via infusion, you may also choose to receive TECENTRIQ as an infusion.

In the second part, TECENTRIQ is given alone for the next 6 months. In this part, you have a choice of injection or infusion. The injection is called TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs). Talk with your doctor to decide which option will work best for you.

TECENTRIQ + chemotherapy given via infusion

TECENTRIQ alone given via infusion OR injection



Not an actual patient; image is AI generated

Comparing infusions and injections

This chart can help you decide on an option.

	TECENTRIQ infusions	TECENTRIQ HYBREZA injections
How it's given	**Into your vein** through an intravenous (IV) line	**Under the skin** as a subcutaneous injection in your thigh
Length of treatment time	**Initial infusion: 60 minutes** **Following infusions: 30 minutes*** Depending on other aspects of treatment, including any other medicines you receive, your total treatment time may be longer. *If the first infusion is well tolerated, all following TECENTRIQ infusions may be given over 30 minutes.	**Each injection: given over the course of about 7 minutes** Depending on other aspects of treatment, including any other medicines you receive, your total treatment time may be longer.
Treatment schedule	**Flexible schedule: every 2, 3, or 4 weeks†** Your doctor will decide how long you will be on treatment. Depending on your treatment plan, you may need to see them more frequently. †TECENTRIQ will be given as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.	**Every 3 weeks‡** Your doctor will decide how long you will be on treatment. Depending on your treatment plan, you may need to see them more frequently. ‡TECENTRIQ HYBREZA will be given as 1875 mg/15 mL every 3 weeks.

Please see full Prescribing Information and additional Important Safety Information throughout this brochure.

TECENTRIQ Hybreza™ atezolizumab/hyaluronidase-tqjs SUBCUTANEOUS INJECTION 1875 mg/30,000 units

TECENTRIQ® atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

Common side effects and how to manage them

When you take TECENTRIQ with chemotherapy, you may experience more side effects than when taking TECENTRIQ alone. The table below shows the side effects that happen most often.

Talk to your doctor about what to expect with either treatment. If you experience any side effects while taking your medicines, it's a good idea to take note of them and discuss them with your doctor to consider how to treat them. TECENTRIQ can cause serious side effects. These can sometimes become severe or life-threatening and can lead to death.

The most common side effects of TECENTRIQ + chemotherapy and TECENTRIQ alone

Since TECENTRIQ is part of both phases of your treatment, you may experience side effects from it at any time. You may also notice that side effects from your chemotherapy carry over into your second part of treatment, when you are receiving TECENTRIQ alone. Some of these side effects can last even after all of your treatments are finished. **Most chemotherapy side effects can be managed. It is important to talk to your healthcare team about how you are feeling and let them know right away if you experience side effects so they can help you manage them.**

	TECENTRIQ + chemotherapy	TECENTRIQ alone
Constipation	✓	
Cough	✓	✓
Decreased appetite	✓	✓
Diarrhea	✓	
Feeling tired or weak		✓
Fever	✓	
Mouth swelling (sometimes with sores)	✓	
Nausea	✓	✓
Numbness, tingling, or pain in the hands or feet	✓	
Shortness of breath	✓	✓
Stomach-area (abdominal) pain	✓	
Vomiting	✓	

Please see full Prescribing Information and additional Important Safety Information throughout this brochure.

Tips to help manage certain side effects

If you experience side effects, always talk to your doctor first. There are some things you can try that may also help:



Low energy: If you're feeling tired, balance activity and rest. Short naps and short walks can both have benefits.



Not much of an appetite: Keep high-protein snacks handy like dried fruits, yogurt, cheese, and eggs. You can also try keeping track of your meals so you know which mealtimes and food work best for you.



Nausea and vomiting: Distract yourself by doing relaxing activities such as listening to music. It may also help to stay hydrated and eat smaller meals more often.

If you are still having side effects, be sure to talk to your doctor. They may be able to make changes to your treatment plan or prescribe medicines to help you stay on track.



Get information to help you prepare for treatment with TECENTRIQ.

Click to download the What to Expect Guide.

SELECT IMPORTANT SAFETY INFORMATION (CONT'D)

Liver problems

- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal

TECENTRIQ® atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

Committed to helping you understand and navigate assistance options for TECENTRIQ

If you are worried about paying for TECENTRIQ, we can help you understand options that may help you. We can find out how much it will cost. We can also help you understand if there are options to help you pay for it.

TECENTRIQ Access Solutions

TECENTRIQ Access Solutions is committed to helping you get the Genentech medicine your doctor prescribed.

At **gene.com/patients/medicines/tecentriq**, you can:

- Find out what we offer
- Learn what to expect from Genentech
- Connect with financial assistance options

Genentech Patient Foundation

The Genentech Patient Foundation provides free TECENTRIQ to people who need it. If you have health insurance, you should try to get other types of financial assistance, if available. You also need to meet income requirements. If you do not have insurance, or if your insurance does not cover your TECENTRIQ, you must meet a different set of income requirements. Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

Please see full Prescribing Information and additional Important Safety Information throughout this brochure.

The Genentech Oncology Co-Pay Assistance Program

For people with commercial health insurance and who meet other eligibility criteria

NO INCOME REQUIREMENTS	PATIENTS PAY AS LITTLE AS $0 FOR TECENTRIQ	ANNUAL BENEFIT LIMIT OF CO-PAY PROGRAM IS $25K

No physical card needed; patients simply need their Member ID.

Call (855) MY-COPAY (855-692-6729) or visit copayassistancenow.com to learn more about the program and get the full list of Terms and Conditions.

The Co-pay Program ("Program") is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. The Program is not available to patients whose prescriptions are reimbursed under any federal, state, or government-funded insurance programs (included but not limited to Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs Programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare programs, the patient will no longer be eligible for the Program.

Under the Program, the patient may be required to pay a co-pay. The final amount owed by a patient may be as little as $0 for the Genentech medicine (see Program specific details available at the Program website). The total patient out-of-pocket cost is dependent on the patient's health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient's out-of-pocket expenses for the Genentech medicine.

All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. No party may seek reimbursement for all or any part of the benefit received through the Program. The value of the Program is intended exclusively for the benefit of the patient. The funds made available through the Program may only be used to reduce the out-of-pocket costs for the patient enrolled in the Program. The Program is not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented a program that adjusts patient cost-sharing obligations based on the availability of support under the Program and/or excludes the assistance provided under the Program from counting towards the patient's deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Program. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply with Genentech Program Terms and Conditions. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time.

Additional terms and conditions apply. Please visit the Co-pay Program website for the full list of Terms and Conditions.

TECENTRIQ®
atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

Where to find more information and support for colon cancer

Here is a list of some of the resources that may help people with colon cancer:

Colorectal Cancer Alliance https://colorectalcancer.org 877-422-2030	The Colorectal Cancer Alliance works to advocate for screening, magnify support, and accelerate research.
Fight CRC https://fightcolorectalcancer.org	Fight CRC focuses on empowering patients and their communities, and is dedicated to strengthening advocacy and research for a colorectal cancer cure.
Global Colon Cancer Association https://www.globalcca.org	The Global Colon Cancer Association advocates for equitable access to screenings, testing, treatments, and care.

For even more resources and support, visit tecentriq.com/colon/resources/helpful-links.

Please be aware that links to third-party sites are provided for convenience only. Genentech is not responsible for the accuracy of the information contained on a third-party site and does not recommend or endorse the content provided on the site.

The information provided by these organizations is meant for informational purposes only and is not meant to replace a doctor's medical advice. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

IMPORTANT SAFETY INFORMATION ABOUT TECENTRIQ AND TECENTRIQ HYBREZA

Who should not receive TECENTRIQ HYBREZA?
Do not receive TECENTRIQ HYBREZA if you are allergic to hyaluronidase or any of the ingredients in TECENTRIQ HYBREZA

What is the most important information about TECENTRIQ and TECENTRIQ HYBREZA?
TECENTRIQ and TECENTRIQ HYBREZA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems
- cough
- shortness of breath
- chest pain

Intestinal problems
- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdomen) pain or tenderness

Liver problems
- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal

Please see full Prescribing Information for TECENTRIQ and TECENTRIQ HYBREZA and the Medication Guides for TECENTRIQ and TECENTRIQ HYBREZA for additional Important Safety Information.

TECENTRIQ Hybreza™
atezolizumab/hyaluronidase-tqjs
SUBCUTANEOUS INJECTION 1875 mg/30,000 units

TECENTRIQ®
atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION (CONT'D)

Hormone gland problems

- headaches that will not go away or unusual headaches
- eye sensitivity to light
- eye problems
- rapid heartbeat
- increased sweating
- extreme tiredness
- weight gain or weight loss
- feeling more hungry or thirsty than usual
- urinating more often than usual
- hair loss
- feeling cold
- constipation
- your voice gets deeper
- dizziness or fainting
- changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems

- decrease in your amount of urine
- blood in your urine
- swelling of your ankles
- loss of appetite

Skin problems

- rash
- itching
- skin blistering or peeling
- painful sores or ulcers in your mouth or your nose, throat, or genital area
- fever or flu-like symptoms
- swollen lymph nodes

Problems can also happen in other organs.

These are not all of the signs and symptoms of immune system problems that can happen with TECENTRIQ or TECENTRIQ HYBREZA. Call or see your healthcare provider right away for any new or worsening signs or symptoms, including:

- Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
- Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
- Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
- Persistent or severe muscle pain or weakness, muscle cramps
- Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

- chills or shaking
- itching or rash
- flushing
- shortness of breath or wheezing
- dizziness
- feeling like passing out
- fever
- back or neck pain

Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had.

IMPORTANT SAFETY INFORMATION (CONT'D)

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with TECENTRIQ or TECENTRIQ HYBREZA. Your healthcare provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with TECENTRIQ or TECENTRIQ HYBREZA. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with TECENTRIQ or TECENTRIQ HYBREZA if you have severe side effects.

Before you receive TECENTRIQ or TECENTRIQ HYBREZA, tell your healthcare provider about all of your medical conditions, including if you:

- have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
- have received an organ or tissue transplant, including corneal transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have received radiation treatment to your chest area
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. TECENTRIQ and TECENTRIQ HYBREZA can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TECENTRIQ or TECENTRIQ HYBREZA. **Females who are able to become pregnant:**
  - Your healthcare provider should do a pregnancy test before you start treatment with TECENTRIQ or TECENTRIQ HYBREZA.
  - You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of TECENTRIQ or TECENTRIQ HYBREZA.

Please see full Prescribing Information for TECENTRIQ and TECENTRIQ HYBREZA and the Medication Guides for TECENTRIQ and TECENTRIQ HYBREZA for additional Important Safety Information.

TECENTRIQ Hybreza™
atezolizumab/hyaluronidase-tqjs
SUBCUTANEOUS INJECTION 1875 mg/30,000 units

TECENTRIQ®
atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION (CONT'D)

- are breastfeeding or plan to breastfeed. It is not known if TECENTRIQ or TECENTRIQ HYBREZA passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of TECENTRIQ or TECENTRIQ HYBREZA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of TECENTRIQ when used alone include:

- feeling tired or weak
- decreased appetite
- nausea
- cough
- shortness of breath

The most common side effects of TECENTRIQ HYBREZA when used alone include:

- feeling tired or weak
- muscle or bone pain
- cough
- shortness of breath
- decreased appetite

The most common side effects of TECENTRIQ and TECENTRIQ HYBREZA when used in colon cancer with fluoropyrimidine and oxaliplatin include:

- nausea
- diarrhea
- numbness, tingling, or pain in the hands or feet
- decreased appetite
- stomach-area (abdominal) pain
- constipation
- cough
- shortness of breath
- mouth swelling (sometimes with sores)
- vomiting
- fever

TECENTRIQ and TECENTRIQ HYBREZA may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of TECENTRIQ and TECENTRIQ HYBREZA. Ask your healthcare provider or pharmacist for more information about the benefits and side effects of TECENTRIQ and TECENTRIQ HYBREZA.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for TECENTRIQ and TECENTRIQ HYBREZA and the Medication Guides for TECENTRIQ and TECENTRIQ HYBREZA for additional Important Safety Information.

Glossary

Adjuvant treatment	Additional treatment given after surgery to help prevent the cancer from coming back.
Biomarker	A biological molecule found in blood, other body fluids, or tissues. It is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may show how likely the body responds to a treatment for a disease or condition.
Chemotherapy	Traditional chemotherapy works throughout the body to destroy fast-growing cells, including both cancer cells and certain healthy cells.
dMMR	A biomarker found in certain patients with colon cancer that can help predict how likely a treatment will work.
DNA	The molecule inside cells that contains the genetic information needed for a person and most other organisms to develop and grow.
Immunotherapy	Treatment that uses a person's own immune system to fight cancer. Immunotherapy boosts the immune system to make it easier for immune cells to find and attack cancer cells.
Infusion	A method of putting fluids, including medicines, into the bloodstream through a vein. Also called intravenous infusion.
Lymph node	A small structure that is part of the immune system. Lymph nodes contain substances that help the body fight infection and disease.
Subcutaneous injection	A method of putting medicine into the body using an injection that goes under the skin.

TECENTRIQ Hybreza™
atezolizumab/hyaluronidase-tqjs
SUBCUTANEOUS INJECTION 1875 mg/30,000 units

TECENTRIQ®
atezolizumab 840 mg/ 1200 mg INJECTION FOR IV USE

Notes

Use these pages to write down any notes or anything you want to remember during your treatment.

For more information, click to visit tecentriq.com/colon

or gene.com/patients/medicines/tecentriq



Genentech
A Member of the Roche Group

© 2026 Genentech, Inc. All rights reserved.
M-US-00032691(v1.0)

TECENTRIQ®
atezolizumab
840 mg / 1200 mg
INJECTION FOR IV USE